Studies conducted so far on tumor samples and normal tissues rely on the use of commercially and non-commercially available antibodies recognizing both α-enolase and MBP-1, this has hampered the possibility to clearly evaluate the relative expression of the two proteins by immunohistochemistry. Here, ENO1 is linked to neoplasm.